Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Teva Pharmaceutical Industries Limited Q1 2026 Earnings Call - Innovative Portfolio Drives 7% Underlying Growth Amid $700M Amylyx Acquisition
Teva Pharmaceutical Industries delivered a solid Q1 2026 performance, with revenues of $4 billion and adjusted EBITDA of $1.1 billion. The company’s pivot to a biopharma model is gaining traction, as ...
- Teva reported Q1 2026 revenues of $4 billion, down 1% year-over-year, or up 7% excluding the Japan divestment and generic Revlimid impact. Adjusted EBITDA rose 2% to $1.1 billion, and non-GAAP EPS grew to $0.53.
- Innovative portfolio revenue surged 41% year-over-year, with Austedo growing 41% to $578 million, UZEDY jumping 62% to $63 million, and AJOVY rising 35% to $196 million.
- Teva announced the acquisition of Amylyx for $700 million upfront, securing ecopipam, a first-in-class D1 receptor antagonist for pediatric Tourette’s syndrome, expected to launch in 2027 with an 80% gross margin profile.
- +7 more takeaways
KT Corporation Q1 2026 Earnings Call - AI Data Center Push and Shareholder Return Amid Profitability Dip
KT Corporation’s Q1 2026 results reflect a transitional quarter. Operating income fell nearly 30% year-over-year, pressured by a high base from last year’s property sales and rising sales and labor co...
- Operating income declined 29.9% YoY to KRW 482.7 billion, primarily due to a high base effect from last year’s Gwangjin property sales and increased labor and sales expenses.
- Revenue fell 1.0% YoY to KRW 6,778 billion, with wireless service revenue slightly up 0.4% despite a January subscriber dip from an early termination fee waiver program.
- Net income contracted 31.5% YoY to KRW 388.3 billion, mirroring the operating income decline and highlighting margin compression in the core business.
- +7 more takeaways
Galapagos NV Q1 2026 Earnings Call - Transforms into Lakefront Biotherapeutics, Secures $713M Gilead Deal for Gamgertamig
Galapagos NV completed a radical transformation in Q1 2026, rebranding as Lakefront Biotherapeutics and closing a landmark $713 million upfront partnership with Gilead for gamgertamig, a BCMA/CD3 T-ce...
- Galapagos NV officially rebranded as Lakefront Biotherapeutics, marking a complete strategic pivot under CEO Henry Gosebruch’s first year in charge.
- The company secured a binding agreement with Gilead for the Ouro Medicines portfolio, centered on gamgertamig, a BCMA/CD3 T-cell engager for autoimmune diseases.
- Gilead’s upfront payment of approximately EUR 713 million (roughly $775 million) unlocks significant capital and modifies legacy terms, granting Lakefront EUR 500 million in flexible funding for independent deals or shareholder returns.
- +9 more takeaways
Village Farms International Q1 2026 Earnings Call - International Medical Exports Surge 171% Drives Record Profitability
Village Farms International delivered a standout first quarter for fiscal 2026, reporting a 27% year-over-year increase in net sales to $50.2 million and a 118% surge in adjusted EBITDA to $9.9 millio...
- Village Farms International reported Q1 2026 net sales of $50.2 million, a 27% increase year-over-year, driven by robust international medical export growth.
- International export sales surged 171% year-over-year and 60% sequentially, reaching a record nearly $15 million, with Germany serving as the primary growth market.
- Consolidated adjusted EBITDA jumped 118% to $9.9 million, with an adjusted EBITDA margin expanding to 20% from 11.4% in Q1 2025.
- +7 more takeaways
MainStreet Bancshares (MNSB) Q1 2026 Earnings Call - Margin Expansion and GovCon Pivot Drive Q1 Execution
MainStreet Bancshares delivered a quarter of disciplined execution, lifting EPS to $0.48 and expanding its net interest margin to 3.47% through aggressive deposit repricing and strategic loan deployme...
- EPS climbed to $0.48, supported by a 5% rise in net interest income and disciplined share repurchases that delivered $0.30 per share of accretion over the last two quarters.
- Net interest margin expanded to 3.47%, with the core margin holding steady at 3.54%, despite a non-recurring $685,000 loss on an Other Real Estate Owned (OREO) disposition.
- Management has effectively neutralized interest rate risk. Over one-third of the loan portfolio is variable or reprices within six months, while 87% of time deposits reprice over the next 12 months, creating a balanced hedge against rate shifts.
- +7 more takeaways
GigaCloud Technology Q1 2026 Earnings Call - Europe Surges 83% as New Classic Integration Begins
GigaCloud Technology reported a robust Q1 2026, delivering 32% revenue growth to $359 million and 53% EPS growth to $1.04, defying a single-digit decline in the broader U.S. furniture market. The resu...
- Revenue grew 32% year-over-year to $359 million, while EPS surged 53% to $1.04, proving the business model’s resilience against a soft U.S. furniture market.
- GigaCloud’s marketplace GMV rose 17% on a trailing twelve-month basis to $1.7 billion, with active third-party sellers up 19% and active buyers up 25%, indicating strong network effects.
- Europe emerged as a high-velocity growth engine, with marketplace GMV jumping 83% quarter-over-quarter, driven by a phased rollout of its 1P-to-3P marketplace model.
- +7 more takeaways
Achieve Life Sciences Q1 2026 Earnings Call - Cytisinicline NDA Resubmission Delayed to Q4 2026, U.S. Manufacturing Transition Underway
Achieve Life Sciences delivered a mixed quarter as its new CEO, Dr. Andrew Goldberg, outlined a clear path forward for cytisinicline despite a setback in FDA approval timing. The company secured a tra...
- Achieve secured a $180 million private placement with up to $174 million in milestone-based warrants exercisable around FDA approval, providing a strong capital base for launch execution.
- CEO Dr. Andrew Goldberg, a physician and healthcare governance expert, joined the company to lead commercialization, bringing a track record of late-stage to market transitions.
- The NDA resubmission is delayed to Q4 2026 due to CGMP observations at a prior third-party manufacturer, not specific to cytisinicline, with Adare Pharma Solutions now the primary U.S. manufacturing partner.
- +7 more takeaways
Docebo Q1 2026 Earnings Call - AI-Driven Substitution and Five-Year Enterprise Deals Accelerate
Docebo reported a strong Q1 2026, marked by a surge in enterprise demand and a decisive shift toward long-term, five-year contracts with major clients. CEO Alessio Artuffo framed the current market as...
- Enterprise demand surged in Q1, with management noting it was the strongest quarter in years, driven by a substitution cycle away from legacy LMS providers.
- Five-year contract terms are becoming the norm for large enterprise deals, as buyers seek to avoid frequent RFP cycles and lock in long-term partnerships.
- The upcoming launch of AgentHub has generated over 500 customer-submitted agent requests at the Inspire conference, signaling high engagement with agentic AI capabilities.
- +7 more takeaways
Precigen Inc. Q1 2026 Earnings Call - PAPZIMEOS Revenue Surges 535% as Commercial Momentum Accelerates
Precigen’s first full quarter of commercial availability for PAPZIMEOS delivered a 535% revenue jump to $21.6 million, driven by broad payer coverage, unrestricted FDA labeling, and rapid adoption acr...
- PAPZIMEOS generated $21.6 million in net product revenue in Q1 2026, up 535% from $3.4 million in Q4 2025, marking the first full quarter of commercial availability.
- Payer coverage now spans over 90% of insured U.S. lives, including comprehensive commercial, Medicare, and Medicaid access, removing significant reimbursement barriers.
- 400 patients are registered in the PAPZIMEOS patient hub, with 25% originating from community practices, signaling broad adoption beyond major academic centers.
- +7 more takeaways
STERIS plc Q4 2026 Earnings Call - Record $6B Revenue, 10% EPS Growth, and $1B Buyback Authorization
STERIS closed a record 2026 with $6 billion in revenue and 10% adjusted EPS growth, powered by a 12% surge in Healthcare service revenue and a 15% rebound in Life Sciences capital equipment. Managemen...
- Fiscal 2026 was a record year with $6 billion in total revenue and 9% as-reported growth, translating to 10% adjusted EPS growth of $10.17 per diluted share despite 80 basis points of tariff headwinds.
- Constant currency organic revenue grew 7% for the full year, driven by a 12% surge in Healthcare service revenue and a 15% rebound in Life Sciences capital equipment spending.
- Healthcare segment revenue hit $4 billion with $1 billion in operating income, while AST crossed $500 million in operating profit, though AST growth was lighter than expected due to customer inventory pullbacks and severe winter weather.
- +7 more takeaways